FDA Approval Insights: Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer
Season 4, Episode 38, Mar 08, 2021, 07:37 PM
In our exclusive interview, Dr. Shitara discussed the significance of the FDA approval of trastuzumab deruxtecan in HER2-positive gastric and GEJ adenocarcinoma and key efficacy and safety data that have been reported with the agent.